Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 3Terminated 2Recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1CNS 1

Conditions

Breast Neoplasms 8Salivary Gland Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pathologic Complete Response 1Hemangiosarcoma 1Heart Failure 1HER2-positive Metastatic Breast Cancer 1HER2-positive Breast Cancer 1HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy 1Endometrial Neoplasms 1Colorectal Neoplasms 1Brain Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 48Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 16Cyclophosphamide 14Cisplatin 14Paclitaxel 13Carboplatin 13Bevacizumab 12Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Leucovorin 10Irinotecan 10Fluorouracil 10Capecitabine 10trastuzumab deruxtecan 9fludarabine 9cemiplimab 8Doxorubicin 8Cetuximab 8abemaciclib 7Trastuzumab 7Pemetrexed 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × Ado-Trastuzumab Emtansine × Clear all
NCT05673928 2026-01-21

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis

NCT05525858 2025-04-27

KOSMOSII

Seoul National University Bundang Hospital

Recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡